The Cancer Biomarkers Market Growth is forecasted to reach USD 42.0 billion by 2029, up from USD 24.5 billion in 2024, at a CAGR of 11.3%. The market's expansion is driven by the increasing incidence of cancer, heightened awareness about early diagnosis, and substantial investments in R&D. The extensive use of biomarkers in diagnosis and drug development further supports this growth, while emerging markets in China, Japan, and India provide additional opportunities.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
Omics Technology Leads Cancer Biomarkers Market by Profiling Method
The cancer biomarkers market is segmented based on profiling methods into omics technologies and imaging technologies. In 2023, the omics technology segment held the largest market share, driven by its high-throughput capabilities in cancer biomarker discovery and diagnosis.
Breast Cancer Segment Poised for Rapid Growth
The market is further categorized by cancer type, including non-Hodgkin's lymphoma, kidney cancer, bladder cancer, thyroid cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, and other cancers. In 2023, the breast cancer segment dominated the market, largely due to the rising global incidence of breast cancer and heightened awareness for early diagnosis, prevention, and treatment.
Instruments Segment Dominates by Product
Based on product type, the cancer biomarkers market is divided into instruments, consumables, and bioinformatics software. The instruments segment held the largest share in 2023, owing to the continuous demand for cancer detection, advancements in instrument technology, and the high accuracy of detection methods.
Diagnostics Segment Leads by Application
The cancer biomarkers market is also segmented by application into risk assessment, prognostics, diagnostics, and research & development. In 2023, the diagnostics segment led the market, driven by the rising incidence of cancer, increasing awareness and acceptance of diagnostic tests, and the introduction of technologically advanced biomarker products.
North America Holds Largest Market Share
Regionally, the global cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America emerged as the largest market in 2023, attributed to the growing prevalence of cancer, increasing research activities, technological advancements, and the expanding use of cancer biomarkers in drug discovery and development.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
Key Market Players
Leading companies in the cancer biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), and Centogene N.V. (Germany).
Related News & Articles
https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp
https://www.marketsandmarkets.com/ResearchInsight/oncology-biomarkers.asp
https://finance.yahoo.com/news/cancer-biomarkers-market-expected-reach-123000501.html
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com